Business, energy, technology, markets and global industry news from Business News Today

SMA

PharmaDeviceNews SMA
Representative image of a pediatric therapy consultation, illustrating how Biogen’s salanersen breakthrough therapy designation could shape the next phase of spinal muscular atrophy treatment and rare neurology care.
Pharma & Biotech

Can salanersen help Biogen defend its rare neurology franchise beyond Spinraza?

Find out how Biogen’s salanersen could reshape spinal muscular atrophy treatment after FDA breakthrough therapy status.

Read More
Pharma & Biotech

Why Novartis Pharma AG’s Itvisma could redefine treatment pathways for older SMA patients

Novartis Pharma AG’s Itvisma gains CHMP support in SMA. Find out how gene therapy could reshape treatment for older patients in Europe.

Read More